Zanubrutinib in combination with rituximab and lenalidomide for the treatment of an elderly diffuse large B-cell lymphoma with large cardiac and renal masses: a case and review of the literature
-
摘要: 本研究主要探讨泽布替尼联合利妥昔单抗及来那度胺治疗虚弱老年弥漫大B细胞淋巴瘤(DLBCL)患者的疗效及安全性。回顾性分析上海交通大学医学院附属瑞金医院2023年1月收治的1例心脏和肾脏大包块且并发心房颤动的虚弱老年DLBCL患者的治疗经过，并进行文献复习。患者，男，68岁，因腰痛，发现肾脏大包块，进一步行PET-CT检查，发现心脏、胃壁、肾脏、腹腔等多部位受累，胃壁活组织检查确诊为DLBCL，该患者高肿瘤负荷且伴有多个不良预后因素，接受泽布替尼联合利妥昔单抗及来那度胺方案治疗后疾病快速获得缓解，且缓解时间持久，同时不良反应可耐受。Abstract: This study focuses on the efficacy and safety of zanubrutinib combined with rituximab and lenalidomide in the treatment of frail elderly patients with diffuse large B-cell lymphoma(DLBCL). We retrospectively analyzed the treatment history of a frail elderly DLBCL patient with large masses in heart and kidney and concomitant with atrial fibrillation who was admitted to Ruijin Hospital of Shanghai Jiaotong University School of Medicine in January 2023. We also performed a literature review. A 68-year-old male with lumbago was found to have a large renal mass. Further PET-CT examination revealed multiple sites of cardiac, gastric wall, renal, and abdominal involvement, and gastric wall biopsy confirmed the diagnosis of DLBCL. This patient with a high tumor burden and multiple adverse prognostic factors was given zanubrutinib combined with rituximab and lenalidomide regimen. A rapid disease remission was obtained and the remission was durable. Furthermore, the adverse effects were tolerable.
-
Key words:
- zanubrutinib /
- lenalidomide /
- diffuse large B-cell lymphoma
-
-
[1] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
[2] Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. Blood, 2010, 116(12): 2040-2045. doi: 10.1182/blood-2010-03-276246
[3] Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte[J]. J Clin Oncol, 2005, 23(18): 4117-4126. doi: 10.1200/JCO.2005.09.131
[4] Bai JF, Han HX, Feng R, et al. Comprehensive geriatric assessment(CGA): a simple tool for guiding the treatment of older adults with diffuse large B-cell lymphoma in China[J]. Oncologist, 2020, 25(8): e1202-e1208. doi: 10.1634/theoncologist.2019-0738
[5] Olivieri A, Gini G, Bocci C, et al. Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA[J]. Oncologist, 2012, 17(5): 663-672. doi: 10.1634/theoncologist.2011-0355
[6] Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019[J]. J Natl Compr Canc Netw, 2019, 17(6): 650-661. doi: 10.6004/jnccn.2019.0029
[7] Luminari S, Viel E, Ferreri AJM, et al. Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase Ⅱ trial conducted by the Fondazione Italiana Linfomi[J]. Hematol Oncol, 2018, 36(1): 68-75. doi: 10.1002/hon.2425
[8] Michalarea V, Low R, Kirkwood AA, et al. Excellent outcomes using rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone(R-GCVP)in patients with DLBCL and cardiac comorbidities[J]. Hematol Oncol, 2019, 37(S2): 425-426. doi: 10.1002/hon.97_2631
[9] Storti S, Spina M, Pesce EA, et al. Rituximab plus bendamustine as front-line treatment in frail elderly(>70 years)patients with diffuse large B-cell non-Hodgkin lymphoma: a phase Ⅱ multicenter study of the Fondazione Italiana Linfomi[J]. Haematologica, 2018, 103(8): 1345-1350. doi: 10.3324/haematol.2017.186569
[10] Boslooper K, Kibbelaar R, Storm H, et al. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome[J]. Leuk Lymphoma, 2014, 55(3): 526-532. doi: 10.3109/10428194.2013.810737
[11] 李江涛, 张春丽, 冯茹, 等. 老年综合评估积分在高龄弥漫大B细胞淋巴瘤患者中的临床意义[J]. 中华老年医学杂志, 2019, 38(2): 170-175. doi: 10.3760/cma.j.issn.0254-9026.2019.02.013
[12] 李江涛, 刘辉, 范芸, 等. 老年初诊弥漫性大B细胞淋巴瘤患者临床特点回顾性分析[J]. 中华老年医学杂志, 2016, 35(2): 201-204. doi: 10.3760/cma.j.issn.0254-9026.2016.02.022
[13] Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4): 271-289. doi: 10.3322/caac.21349
[14] Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6, 382 cases using WHO classification in a single institution[J]. Diagn Pathol, 2011, 6: 77. doi: 10.1186/1746-1596-6-77
[15] Aoki K, Takahashi T, Tabata S, et al. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2013, 54(11): 2441-2447. doi: 10.3109/10428194.2013.780654
[16] Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older[J]. Leuk Lymphoma, 2012, 53(1): 43-49. doi: 10.3109/10428194.2011.600486
[17] Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide[J]. Eur J Cancer, 2013, 49(1): 219-230. doi: 10.1016/j.ejca.2012.05.005
[18] Zhang Y, Zhao X, Tao J. Epigenetics, c-Myc and aggressive B-cell lymphomas[J]. Oncotarget, 2012, 3(11): 1264-1265. doi: 10.18632/oncotarget.748
[19] Aw A, Brown JR. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies[J]. Drugs Aging, 2017, 34(7): 509-527. doi: 10.1007/s40266-017-0468-4
[20] Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J]. Nature, 2010, 463(7277): 88-92. doi: 10.1038/nature08638
[21] 吴凌, 张翼鷟, 夏冰, 等. 依布替尼通过新型途径克服弥漫大B细胞淋巴瘤细胞耐药机制的研究[J]. 中华血液学杂志, 2017, 38(12): 1036-1042. doi: 10.3760/cma.j.issn.0253-2727.2017.12.006
[22] Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy[J]. Blood, 2009, 114(21): 4713-4720. doi: 10.1182/blood-2009-04-217687
[23] Morin RD, Assouline S, Alcaide M, et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas[J]. Clin Cancer Res, 2016, 22(9): 2290-2300. doi: 10.1158/1078-0432.CCR-15-2123
[24] Hartert KT, Wenzl K, Krull JE, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL[J]. Leukemia, 2021, 35(2): 522-533. doi: 10.1038/s41375-020-0766-4
[25] Yang Y, Shaffer AL 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma[J]. Cancer Cell, 2012, 21(6): 723-737. doi: 10.1016/j.ccr.2012.05.024
[26] Westin JR, Nastoupil LJ, Fayad L, et al. Smart start: rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma: final phase Ⅱresults[J]. Blood, 2019, 134(Suppl 1): 1581.
[27] Xu PP, Shi ZY, Qian Y, et al. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study[J]. Lancet Healthy Longev, 2022, 3(7): e481-e490. doi: 10.1016/S2666-7568(22)00123-4
[28] Westin JR, Nastoupil L, Hagemeister F, et al. Smart start: final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(S15): 7508.
[29] Ahn IE. Cardiovascular adverse events of ibrutinib[J]. Blood, 2019, 134(22): 1881-1882. doi: 10.1182/blood.2019002805
[30] Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma[J]. Am J Hematol, 2019, 94(12): 1353-1363. doi: 10.1002/ajh.25638
-
下载:
图(2)
计量
- 文章访问数: 604
- PDF下载数: 73
- 施引文献: 0